Kala launches Eysuvis for short-term dry eye treatment

Eysuvis is now available for the short-term treatment of dry eye disease, according to a press release from Kala Pharmaceuticals.
Eysuvis uses Kala’s proprietary Ampplify mucus-penetrating particle drug delivery technology for enhanced penetration of loteprednol etabonate into target ocular surface tissue to treat signs and symptoms of dry eye disease. The treatment also offers a favorable tolerability and safety profile and has the potential to completement existing therapies, the release said.
“We are excited to announce our second product launch in 2 years, with Eysuvis now

Full Story →